New data has been published by VisionCare Ophthalmic Technologies in Clinical Ophthalmology, which provides long-term data results for safety and effectiveness of the implantable miniature telescope for patients with end-stage, age-related macular degeneration.
Here are six things to know about the study:
1. There were 217 enrolled patients, with an average age of 76.
2. After a comparative evaluation, mean best-corrected distance visual acuity improvement from the baseline to 60 months was 2.41±2.69 lines in all patients.
3. Quality of life scores were significantly higher in patients between 65 to 75 years old then in patients 75 or older.
4. Both younger and older patients had clinically significant visual acuity gains at two years as well as five years after telescope implant.
5. Significant adverse events included four corneal transplant, two in the younger group and two in the older group.
6. The IMT was removed in one patient from the younger group, and 10 were removed in the older group.
The researchers concluded that "long-term results show substantial retention of improvement in BDCVA… Younger patients retained more vision than their older counterparts and had fewer adverse events."